The use of adalimumab in the management of refractory Crohn’s disease
Open Access
- 7 December 2007
- journal article
- clinical trial
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 27 (4), 308-315
- https://doi.org/10.1111/j.1365-2036.2007.03583.x
Abstract
Background Adalimumab is a humanized monoclonal antibody targeting tumour necrosis factor‐α. Recent clinical trials have demonstrated its efficacy in Crohn’s disease; however, experience in clinical practice remains limited. Aim To investigate the efficacy and safety of adalimumab in the clinical setting. Methods The clinical outcomes of patients with medically refractory Crohn’s disease treated with adalimumab in the Western General Hospital Edinburgh, over a 3‐year period (2003–2006), were studied. Results Twenty‐two (14 females; age at therapy: 32.6 years) patients were treated using an 80/40 mg induction regimen followed by fortnightly 40 mg treatment. All had proven refractory/intolerant to corticosteroids and immunosuppression. Twenty patients had had previous infliximab infusions – of these eight (36%), six (27%), three (14%) had previous infusion reactions, no response and lost response to infliximab, respectively. Over a period of 1.0 years (IQR: 0.62–2.5), Kaplan–Meier analyses showed that 68% (seven nonresponders) were in clinical remission and 67% (five surgery – discounting oral CD) avoided further surgery for active disease. 59% required dose escalation to 40 mg weekly (0.55 years; IQR: 0.22–1.4). Three (50%) primary nonresponders to infliximab achieved remission. Two patients developed serious infective complications and one patient developed lung cancer. Conclusions Adalimumab is efficacious in refractory Crohn’s disease, with benefit observed in infliximab primary nonresponders. However, many patients require escalation of dosing regimen.Keywords
This publication has 18 references indexed in Scilit:
- Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk?Gut, 2007
- Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trialGut, 2007
- Adalimumab for Maintenance of Clinical Response and Remission in Patients With Crohn’s Disease: The CHARM TrialGastroenterology, 2007
- Anti-TNF- therapy for orofacial granulomatosis: proceed with cautionGut, 2006
- Rates of serious infection, including site‐specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti–tumor necrosis factor therapy: Results from the British Society for Rheumatology Biologics RegisterArthritis & Rheumatism, 2006
- Anti-TNF Antibody Therapy in Rheumatoid Arthritis and the Risk of Serious Infections and MalignanciesJAMA, 2006
- Human Anti–Tumor Necrosis Factor Monoclonal Antibody (Adalimumab) in Crohn’s Disease: the CLASSIC-I TrialGastroenterology, 2006
- Infliximab for Induction and Maintenance Therapy for Ulcerative ColitisNew England Journal of Medicine, 2005
- Maintenance infliximab for Crohn's disease: the ACCENT I randomised trialThe Lancet, 2002
- Infliximab for the Treatment of Fistulas in Patients with Crohn's DiseaseNew England Journal of Medicine, 1999